Astellas Pharma Inc. (ALPMY)
OTCMKTS
· Delayed Price · Currency is USD
10.07
+0.50 (5.22%)
Apr 25, 2025, 4:00 PM EDT
Astellas Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Revenue | 1,912,323 | 1,603,672 | 1,518,619 | 1,296,163 | 1,249,528 | Upgrade
|
Revenue Growth (YoY) | 19.25% | 5.60% | 17.16% | 3.73% | -3.94% | Upgrade
|
Cost of Revenue | 349,206 | 292,485 | 288,353 | 253,009 | 246,063 | Upgrade
|
Gross Profit | 1,563,117 | 1,311,187 | 1,230,266 | 1,043,154 | 1,003,465 | Upgrade
|
Selling, General & Admin | 843,032 | 740,110 | 630,272 | 548,840 | 504,316 | Upgrade
|
Research & Development | 327,651 | 294,187 | 276,128 | 246,010 | 224,489 | Upgrade
|
Other Operating Expenses | 23,124 | 53,464 | 53,778 | 1,876 | -35 | Upgrade
|
Operating Expenses | 1,330,569 | 1,186,581 | 998,614 | 825,009 | 752,533 | Upgrade
|
Operating Income | 232,548 | 124,606 | 231,652 | 218,145 | 250,932 | Upgrade
|
Interest Expense | -17,677 | -7,423 | -3,217 | -2,315 | -2,118 | Upgrade
|
Interest & Investment Income | 7,874 | 8,851 | 5,253 | 862 | 760 | Upgrade
|
Earnings From Equity Investments | -259 | -3,165 | 1,260 | 489 | 478 | Upgrade
|
Currency Exchange Gain (Loss) | -18,600 | -807 | -10,124 | 8,172 | -2,332 | Upgrade
|
Other Non Operating Income (Expenses) | 2 | -1,723 | 2,303 | -2,431 | 72 | Upgrade
|
EBT Excluding Unusual Items | 203,888 | 120,339 | 227,127 | 222,922 | 247,792 | Upgrade
|
Merger & Restructuring Charges | -15,500 | -25,407 | -4,510 | -19,556 | -9,293 | Upgrade
|
Gain (Loss) on Sale of Investments | - | -253 | -5,007 | 5,084 | 10,558 | Upgrade
|
Gain (Loss) on Sale of Assets | 1,049 | 9,735 | 212 | 24,234 | 24 | Upgrade
|
Asset Writedown | -174,900 | -78,931 | -83,964 | -74,850 | -101,746 | Upgrade
|
Legal Settlements | - | -514 | -1,497 | -948 | -2,012 | Upgrade
|
Other Unusual Items | 16,700 | - | - | - | - | Upgrade
|
Pretax Income | 31,237 | 24,969 | 132,361 | 156,886 | 145,323 | Upgrade
|
Income Tax Expense | -19,510 | 7,924 | 33,647 | 32,800 | 24,734 | Upgrade
|
Net Income | 50,747 | 17,045 | 98,714 | 124,086 | 120,589 | Upgrade
|
Net Income to Common | 50,747 | 17,045 | 98,714 | 124,086 | 120,589 | Upgrade
|
Net Income Growth | 197.72% | -82.73% | -20.45% | 2.90% | -38.29% | Upgrade
|
Shares Outstanding (Basic) | 1,790 | 1,793 | 1,820 | 1,850 | 1,857 | Upgrade
|
Shares Outstanding (Diluted) | 1,797 | 1,800 | 1,825 | 1,851 | 1,858 | Upgrade
|
Shares Change (YoY) | -0.14% | -1.39% | -1.38% | -0.41% | -1.03% | Upgrade
|
EPS (Basic) | 28.35 | 9.50 | 54.24 | 67.08 | 64.93 | Upgrade
|
EPS (Diluted) | 28.24 | 9.47 | 54.09 | 67.05 | 64.90 | Upgrade
|
EPS Growth | 198.21% | -82.49% | -19.33% | 3.31% | -37.64% | Upgrade
|
Free Cash Flow | 157,509 | 134,419 | 291,326 | 226,705 | 275,459 | Upgrade
|
Free Cash Flow Per Share | 87.64 | 74.69 | 159.63 | 122.50 | 148.24 | Upgrade
|
Dividend Per Share | 74.000 | 70.000 | 60.000 | 50.000 | 42.000 | Upgrade
|
Dividend Growth | 5.71% | 16.67% | 20.00% | 19.05% | 5.00% | Upgrade
|
Gross Margin | 81.74% | 81.76% | 81.01% | 80.48% | 80.31% | Upgrade
|
Operating Margin | 12.16% | 7.77% | 15.25% | 16.83% | 20.08% | Upgrade
|
Profit Margin | 2.65% | 1.06% | 6.50% | 9.57% | 9.65% | Upgrade
|
Free Cash Flow Margin | 8.24% | 8.38% | 19.18% | 17.49% | 22.05% | Upgrade
|
EBITDA | 431,680 | 282,446 | 337,390 | 297,829 | 323,584 | Upgrade
|
EBITDA Margin | 22.57% | 17.61% | 22.22% | 22.98% | 25.90% | Upgrade
|
D&A For EBITDA | 199,132 | 157,840 | 105,738 | 79,684 | 72,652 | Upgrade
|
EBIT | 232,548 | 124,606 | 231,652 | 218,145 | 250,932 | Upgrade
|
EBIT Margin | 12.16% | 7.77% | 15.25% | 16.83% | 20.08% | Upgrade
|
Effective Tax Rate | - | 31.74% | 25.42% | 20.91% | 17.02% | Upgrade
|
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.